Our top pick for
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
AstraZeneca (AZN) is a major British-Swedish drug manufacturer, perhaps best known globally for the development of its COVID-19 vaccine with Oxford University. The company is a merger between Swedish firm Astra AB and the British Zeneca Group. AZN is listed on the London Stock Exchange as well as on the New York Stock Exchange and the Bombay Stock Exchange.
|52-week range||US$46.1106 - US$61.34|
|50-day moving average||US$58.9403|
|200-day moving average||US$56.9868|
|Dividend yield||US$2.8 (4.57%)|
|Earnings per share (TTM)||US$1.4355|
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-10-14)||0.02%|
|1 month (2021-09-24)||-1.11%|
|3 months (2021-07-23)||2.49%|
|6 months (2021-04-23)||14.20%|
|1 year (2020-10-23)||14.77%|
|2 years (2019-10-24)||26.31%|
|3 years (2018-10-24)||57.63%|
|5 years (2016-10-24)||98.40%|
Valuing AstraZeneca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, AstraZeneca shares trade at around 43x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9855. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$6.6 billion (£4.8 billion).
The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$29.5 billion|
|Operating margin TTM||13.41%|
|Gross profit TTM||US$21.4 billion|
|Return on assets TTM||3.7%|
|Return on equity TTM||25.68%|
|Market capitalisation||US$191.5 billion|
TTM: trailing 12 months
There are currently 7.2 million AstraZeneca shares held short by investors – that's known as AstraZeneca's "short interest". This figure is 9.5% up from 6.5 million last month.
There are a few different ways that this level of interest in shorting AstraZeneca shares can be evaluated.
AstraZeneca's "short interest ratio" (SIR) is the quantity of AstraZeneca shares currently shorted divided by the average quantity of AstraZeneca shares traded daily (recently around 6.3 million). AstraZeneca's SIR currently stands at 1.14. In other words for every 100,000 AstraZeneca shares traded daily on the market, roughly 1140 shares are currently held short.
However AstraZeneca's short interest can also be evaluated against the total number of AstraZeneca shares, or, against the total number of tradable AstraZeneca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AstraZeneca's short interest could be expressed as 0% of the outstanding shares (for every 100,000 AstraZeneca shares in existence, roughly 0 shares are currently held short) or 0.0027% of the tradable shares (for every 100,000 tradable AstraZeneca shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AstraZeneca.
Find out more about how you can short AstraZeneca stock.
Dividend payout ratio: 61.54% of net profits
Recently AstraZeneca has paid out, on average, around 61.54% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.29% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca shareholders could enjoy a 2.29% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about $2.8 per share.
AstraZeneca's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AstraZeneca's most recent dividend payout was on 12 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 August 2021 (the "ex-dividend date").
AstraZeneca's shares were split on a 2:1 basis on 26 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca shares which in turn could have impacted AstraZeneca's share price.
Over the last 12 months, AstraZeneca's shares have ranged in value from as little as US$46.1106 up to US$61.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca's is 0.1778. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Google's re-entry into the premium phone market relies strongly on the smarts of its new Tensor processor.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder.com.au has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product. You can learn more about how we make money here.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.